TriangleNCT00644189 · REGISTRY CONDITION SEARCH
Oral Clofarabine for Relapsed/Refractory Non-Hodgkin Lymphoma
Found through the registry condition index, not selected as a treatment recommendation. This discovery collection was restricted to studies with posted results.
- Phase
- PHASE1, PHASE2
- Status at capture
- COMPLETED
- Registry last update
- 2023-03-15
Oral clofarabine is related to two intravenous chemotherapy drugs used for this disease and works in two different ways. It affects the development of new cancer cells by blocking two enzymes that cancer cells need to reproduce. When these enzymes are blocked, the cancer call can no longer prepare the DNA needed to make new cells. Clofarabine also encourages existing cancer cells to die by disturbing components within the cancer cell. This causes the release of a substance that is fatal to the cell. This trial studies the efficacy of oral clofarabine in the treatment of relapsed non-Hodgkin lymphomas.
Open the original ClinicalTrials.gov record → · Download preserved record
What did the study report?
Outcomes, safety and baseline populations are separate source sections. Quality-of-life measures appear under their original outcome titles.
Participant flow
Baseline characteristics
All Phase I-II Participants: Overall Response Rate (ORR)
Phase I Participants Only: Overall Response Rate (ORR)
Phase I-II Participants Treated at the RP2D (3mg): Overall Response Rate (ORR)
All Phase I-II Participants: Progression-free Survival (PFS)
All Phase I-II Participants: Overall Survival (OS)
All Phase I-II Participants: Safety
Phase I Participants Treated at the RP2D (3mg): Overall Response Rate (ORR)
Phase I Participants: Progression-free Survival (PFS)
All Phase I Participants: Overall Survival (OS)
Phase I Participants: Safety
Adverse events
Limitations, agreements, and source contact
Who could take part
- eligibility Criteria
- Inclusion Criteria: * Histologically confirmed relapsed or refractory NHL that includes: follicular lymphoma of any grade; marginal zone lymphoma; small lymphocytic lymphoma/chronic lymphocytic leukemia; mantle cell lymphoma; lymphoplasmacytic lymphoma; low-grade B-cell lymphoma not otherwise specified; diffuse large B-cell lymphoma, anaplastic large cell lymphoma, peripheral T-cell lymphoma, angioimmunoblastic T-cell lymphoma. * One or more prior line of chemotherapy, immunotherapy, or radioimmunotherapy. * Measurable disease on cross sectional imaging of at least 2cm. * ECOG Performance Status 0-2 * 18 years of age or older * Life expectancy of greater than 3 months * Normal organ and marrow function as outlined in the protocol * Must agree to use adequate contraception prior to study entry and for the duration of study participation Exclusion Criteria: * Patients who have had chemotherapy, rituximab, or radiotherapy within 4 weeks, or radioimmunotherapy within 8 weeks prior to entering the study * Receiving any other investigational agent * Known brain metastases * History of allergic reactions attributed to compounds of similar chemical or biologic composition to Clofarabine * Systemic fungal, bacterial, viral, or other infection not controlled * Pregnant or lactating * Prior history of another malignancy (except for non-melanoma skin cancer or in situ cervical or breast cancer) unless disease free for over one year * Uncontrolled intercurrent illness including, but not limited to ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements * Prior allogeneic stem cell transplantation
- healthy Volunteers
- false
- minimum Age
- 18 Years
- sex
- ALL
- std Ages
- ADULT
- OLDER_ADULT
Treatment arms and interventions
- arm Groups
- description
- Taken orally once a day (in the AM) on days 1 through 21 of a 28-day cycle for a maximum of 6 cycles.
- intervention Names
- Drug: Clofarabine
- label
- Clofarabine
- type
- OTHER
- interventions
- arm Group Labels
- Clofarabine
- description
- Taken orally once a day (in the AM) on days 1 through 21 of a 28-day cycle for a maximum of 6 cycles.
- name
- Clofarabine
- other Names
- Clolar
- type
- DRUG
Study design
- allocation
- NA
- intervention Model
- SINGLE_GROUP
- masking Info
- masking
- NONE
- primary Purpose
- TREATMENT
Enrollment
- count
- 50
- type
- ACTUAL
Registered outcome plans (not posted results)
- primary Outcomes
- description
- Determine the efficacy of oral clofarabine (any of the 4 dose levels: 1mg, 2mg, 4mg, and 3mg) in all phase I-II trial patients with relapsed/refractory non-Hodgkin lymphomas. Per Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.0) for target lesions and assessed by MRI: Complete Response (CR), Disappearance of all target lesions; Partial Response (PR), \>=30% decrease in the sum of the longest diameter of target lesions; Overall Response (OR) = CR + PR.
- measure
- All Phase I-II Participants: Overall Response Rate (ORR)
- time Frame
- after at most 6 28-day cycles
- description
- Determine the efficacy of oral clofarabine (any of the 4 dose levels: 1mg, 2mg, 4mg, and 3mg) in all phase I trial patients with relapsed/refractory non-Hodgkin lymphomas. Per Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.0) for target lesions and assessed by MRI: Complete Response (CR), Disappearance of all target lesions; Partial Response (PR), \>=30% decrease in the sum of the longest diameter of target lesions; Overall Response (OR) = CR + PR.
- measure
- Phase I Participants Only: Overall Response Rate (ORR)
- time Frame
- after at most 6 28-day cycles
- secondary Outcomes
- description
- To determine the efficacy of oral clofarabine (3mg) in patients with relapsed/refractory non-Hodgkin lymphoma. The 3mg dose was declared the recommended phase 2 dose (RP2D) from phase I. Per Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.0) for target lesions and assessed by MRI: Complete Response (CR), Disappearance of all target lesions; Partial Response (PR), \>=30% decrease in the sum of the longest diameter of target lesions; Overall Response (OR) = CR + PR.
- measure
- Phase I-II Participants Treated at the RP2D (3mg): Overall Response Rate (ORR)
- time Frame
- after at most 6 28-day cycles
- description
- Determine the progression-free survival rate among all phase I-II trial participants who are treated with any of the 4 dose levels of oral clofarabine (1mg, 2mg, 4mg, or 3mg). Progression is defined using Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.0), as a 20% increase in the sum of the longest diameter of target lesions, or a measurable increase in a non-target lesion, or the appearance of new lesions.
- measure
- All Phase I-II Participants: Progression-free Survival (PFS)
- time Frame
- at 1 and 2 years
- description
- Determine the overall survival rate among all phase I-II trial participants who are treated with any of the 4 dose levels of oral clofarabine (1mg, 2mg, 4mg, or 3mg)
- measure
- All Phase I-II Participants: Overall Survival (OS)
- time Frame
- 3 years
- description
- Grade 3-4 toxicities among all phase I-II trial participants who are treated with any of the 4 dose levels of oral clofarabine (1mg, 2mg, 4mg, or 3mg)
- measure
- All Phase I-II Participants: Safety
- time Frame
- during 6 28-day cycles and 90 days out
- description
- To determine the efficacy of oral clofarabine (3mg) in patients with relapsed/refractory non-Hodgkin lymphoma. The 3mg dose was declared the recommended phase 2 dose (RP2D) from phase I. Per Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.0) for target lesions and assessed by MRI: Complete Response (CR), Disappearance of all target lesions; Partial Response (PR), \>=30% decrease in the sum of the longest diameter of target lesions; Overall Response (OR) = CR + PR.
- measure
- Phase I Participants Treated at the RP2D (3mg): Overall Response Rate (ORR)
- time Frame
- after at most 6 28-day cycles
- description
- Determine the progression-free survival rate among all phase I trial participants who are treated with any of the 4 dose levels of oral clofarabine (1mg, 2mg, 4mg, or 3mg). Progression is defined using Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.0), as a 20% increase in the sum of the longest diameter of target lesions, or a measurable increase in a non-target lesion, or the appearance of new lesions.
- measure
- Phase I Participants: Progression-free Survival (PFS)
- time Frame
- at 17 months
- description
- Determine the overall survival rate among all phase I trial participants who are treated with any of the 4 dose levels of oral clofarabine (1mg, 2mg, 4mg, or 3mg)
- measure
- All Phase I Participants: Overall Survival (OS)
- time Frame
- at 17 months
- description
- Grade 2-4 toxicities and grade 3-4 infections among all phase I trial participants who are treated with any of the 4 dose levels of oral clofarabine (1mg, 2mg, 4mg, or 3mg)
- measure
- Phase I Participants: Safety
- time Frame
- during 6 28-day cycles and 90 days out
Full study description
- brief Summary
- Oral clofarabine is related to two intravenous chemotherapy drugs used for this disease and works in two different ways. It affects the development of new cancer cells by blocking two enzymes that cancer cells need to reproduce. When these enzymes are blocked, the cancer call can no longer prepare the DNA needed to make new cells. Clofarabine also encourages existing cancer cells to die by disturbing components within the cancer cell. This causes the release of a substance that is fatal to the cell. This trial studies the efficacy of oral clofarabine in the treatment of relapsed non-Hodgkin lymphomas.
- detailed Description
- * Each treatment cycle lasts four weeks during which time the participant will be taking study drug for the first three weeks only. Participants will be supplied with a study medication-dosing calendar for each treatment cycle. * Clofarabine is a tablet that will be taken orally in the morning once daily on days 1 through 21 of each 28-day cycle. Participants can receive up to a total of 6 cycles if they do not experience any unacceptable side effects and if their cancer does not get worse. * The following tests and procedures will be performed at specified intervals through out the treatment period: blood tests, physical examinations, vital signs, radiological exams and urine tests.
Source references
Source notices and limitations
Discovery and provenance
- release id
- ctgov-registry-1336d216cbd1bbff780dac70
- edge id
- nct-edge-c457d05b047cd560854c
- requested nct id
- NCT00644189
- primary nct id
- NCT00644189
- source kind
- ctgov_condition_query
- source record id
- Source null
- source file sha256
- e270600534699a676fe83226e7a7b0f73aeb00c1d0a05cfc115c748864ad8173
- payload sha256
- 72d510058582838439c1cc8f35dda3420bed34262879efb4d42d10e23a21ecd3
- payload
- clinical indication matching status
- condition_index_match_asserted_by_registry_not_reviewed
- end exclusive
- true
- id
- nct-edge-c457d05b047cd560854c
- link basis
- returned_by_explicit_condition_and_posted_results_filter_query
- nct id
- NCT00644189
- occurrences
- context exact
- NCT00644189
- end
- 11
- exact text
- NCT00644189
- start
- 0
- offset unit
- unicode_code_points
- query cond
- Peripheral T-Cell Non-Hodgkin Lymphoma
- query disease state id
- ds-peripheral-t-cell-non-hodgkin-lymphoma
- source file
- /Users/arunverma/Documents/ChatGPT/Cancer Statistics Website/research-data/2026-09-10/clinicaltrials-condition/round-0000/raw/cond-peripheral-t-cell-non-hodgkin-lymphoma-000.json
- source file sha256
- e270600534699a676fe83226e7a7b0f73aeb00c1d0a05cfc115c748864ad8173
- source json pointer
- /studies/123/protocolSection/identificationModule/nctId
- source kind
- ctgov_condition_query
- source record id
- Source null
- source string basis
- parsed_JSON_string_unmodified
- source string sha256
- 9b2ed232592b3620a401f10ddacd2f44bd4480365d5188db2aa9dc6686581ea2
Preserved source evidence · Not medical advice